Direkt zum Inhalt
Merck
  • Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.

Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2015-04-10)
Samuel W Cramer, Laurentiu S Popa, Russell E Carter, Gang Chen, Timothy J Ebner
ZUSAMMENFASSUNG

The Ca(2+) channelopathies caused by mutations of the CACNA1A gene that encodes the pore-forming subunit of the human Cav2.1 (P/Q-type) voltage-gated Ca(2+) channel include episodic ataxia type 2 (EA2). Although, in EA2 the emphasis has been on cerebellar dysfunction, patients also exhibit episodic, nonmotoric abnormalities involving the cerebral cortex. This study demonstrates episodic, low-frequency oscillations (LFOs) throughout the cerebral cortex of tottering (tg/tg) mice, a widely used model of EA2. Ranging between 0.035 and 0.11 Hz, the LFOs in tg/tg mice can spontaneously develop very high power, referred to as a high-power state. The LFOs in tg/tg mice are mediated in part by neuronal activity as tetrodotoxin decreases the oscillations and cortical neuron discharge contain the same low frequencies. The high-power state involves compensatory mechanisms because acutely decreasing P/Q-type Ca(2+) channel function in either wild-type (WT) or tg/tg mice does not induce the high-power state. In contrast, blocking l-type Ca(2+) channels, known to be upregulated in tg/tg mice, reduces the high-power state. Intriguingly, basal excitatory glutamatergic neurotransmission constrains the high-power state because blocking ionotropic or metabotropic glutamate receptors results in high-power LFOs in tg/tg but not WT mice. The high-power LFOs are decreased markedly by acetazolamide and 4-aminopyridine, the primary treatments for EA2, suggesting disease relevance. Together, these results demonstrate that the high-power LFOs in the tg/tg cerebral cortex represent a highly abnormal excitability state that may underlie noncerebellar symptoms that characterize CACNA1A mutations.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Bromwasserstoffsäure, ACS reagent, 48%
Supelco
Chlormethan -Lösung, 200 μg/mL in methanol, analytical standard
Sigma-Aldrich
Monoklonaler Anti-α-Tubulin-Antikörper in Maus hergestellte Antikörper, ascites fluid, clone B-5-1-2
Sigma-Aldrich
Bromwasserstoffsäure, reagent grade, 48%
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
Bromwasserstoffsäure, 48 wt. % in H2O, ≥99.99%
Sigma-Aldrich
Hydrogenbromid -Lösung, 33 wt. % in acetic acid
Sigma-Aldrich
Koffein, anhydrous, 99%, FCC, FG
Sigma-Aldrich
Indol, ≥99%
Sigma-Aldrich
Koffein, powder, ReagentPlus®
Sigma-Aldrich
4-Aminopyridin, 98%
Supelco
Koffein, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
4-Aminopyridin, ≥99%
USP
Koffein, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Pyridin -hydrochlorid, 98%
USP
Koffein-Schmelzpunkt-Standard, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
DL-2-Amino-5-phosphono-valeriansäure, solid
Sigma-Aldrich
Acetazolamid, ≥99%, powder
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Indol, ≥99%, FG
Supelco
Coffein Schmelzpunktstandard, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Chlormethan -Lösung, 1.0 M in tert-butyl methyl ether, anhydrous
Sigma-Aldrich
DNQX, ≥98% (TLC)
Supelco
Koffein, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Koffein, Sigma Reference Standard, vial of 250 mg
Supelco
Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Schmelzpunktstandard 235-237°C, analytical standard
Sigma-Aldrich
Koffein, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
Chlormethan -Lösung, 1.0 M in diethyl ether
Supelco
Mettler Toledo Calibration Substance ME 18872, Caffeine, traceable to primary standards (LGC)